Long-term outcomes by biomarker probabilities in patients with GVHD that is resistant to early treatment. Patients with GVHD in a validation cohort (n = 68) who did not have a complete response to systemic treatment were subdivided into low (N = 49; blue) and high (N = 19; red) groups based on biomarker probabilities. Differences in 12-month cumulative incidence of NRM (low 14% vs high 75%, P < .001) and overall survival (low 78% vs high 14%, P < .001) were highly significant. Adapted from Major-Monfried et al⁴⁹  with permission.